Navigation Links
Quark Pharmaceuticals Announces Poster Presentations at RNAi Europe 2008
Date:9/17/2008

es raises the necessity to target more than one gene at a time. At the same time, simultaneous delivery of different siRNAs targeting one and the same gene can increase the treatment specificity and reduce off-target effects.

Dr. Daniel Zurr, Quark's Chief Executive Officer, stated, "These poster presentations highlight our ongoing work to establish Quark's leadership in the field of RNAi by developing novel IP and expertise covering technology platforms that facilitate development of siRNA therapeutics. With the industry's most robust portfolio of siRNA therapeutics currently under evaluation in human clinical trials, Quark has proven its ability to advance siRNA products from discovery to the clinic."

About Quark Pharmaceuticals, Inc.

Quark Pharmaceuticals, Inc. is a development-stage pharmaceutical company engaged in discovering and developing novel therapeutic RNAi drug candidates. Quark has a fully integrated drug development platform that spans therapeutic target identification to drug development. Quark's RNAi technology includes novel siRNA structures and chemistry that the Company believes provide Quark with freedom to operate in the siRNA intellectual property arena, as well as the ability to deliver siRNA non invasively to organs including the eye, ear, kidney, lung, spinal cord and brain.

PF-4523655 (RTP801i-14), currently in Phase II clinical trials, is a synthetic, chemically modified, siRNA molecule to inhibit the expression of the gene RTP801, licensed to Pfizer. In addition, Quark's current clinical pipeline includes AKIi-5, developed by Quark for the prevention of acute kidney injury (AKI) following major cardiac surgery, currently in Phase I/IIa clinical trials via systemic delivery and DGFi with open IND for prevention of delayed graft function in kidney transplantation. Based on publicly available information, Quark believes AKIi-5 was the first siRNA delivered systemically in a human clinical trial.

In additio
'/>"/>

SOURCE Quark Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. FDA Approves Quark IND for DGFi, an siRNA Therapeutic Based on Silence Therapeutics Unique Proprietary Chemistry
2. Quark Pharmaceuticals to Participate in 9th Annual Beyond Genome Conference
3. Cequent Pharmaceuticals Meets Novartis Option Fund Milestone; Continues to Next Phase to Validate Inflammatory Bowel Disease Targets in Vivo
4. David Hsia, Ph.D. Joins Kinex Pharmaceuticals Board of Directors
5. Trubion Pharmaceuticals Wins Patent Opposition - Genentech / Biogen Idec European Patent Revoked
6. Dr. Paul Korner Joins Ferring Pharmaceuticals as Vice President, Medical Affairs
7. Rib-X Pharmaceuticals, Inc. Announces Formation of Clinical Advisory Board
8. VIA Pharmaceuticals to Host Investor Science Briefing on the Role of Inflammation in Cardiovascular Disease on Tuesday, September 16
9. Peregrine Pharmaceuticals Reports Financial Results for the First Quarter of Fiscal Year 2009
10. Oramed Pharmaceuticals Partners With ETI Karle Clinical to Conduct Phase 2B Trials on Its Oral Insulin Capsule, ORMD 0801
11. Genesis Pharmaceuticals Completes Reverse Stock Split and Will Trade Under a New Symbol
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... SAN JOSE, Calif. , Aug. 20, 2014 ... UCSD highlights the transformative collaboration between the school,s ... (IoT).  As part of the Intel® Software Academic ... between computer sciences and the human body.  ... The study exhibits the work of ...
(Date:8/19/2014)... NJ (PRWEB) August 20, 2014 ... and regenerative medicine is an inadequate vascular supply. ... constructs and decellularized tissues is critical for successful ... have attempted to mitigate deficiencies in vascularization and ... adding scaffold bioactivity, optimizing scaffold design and architecture, ...
(Date:8/19/2014)... 2014 Cellgen Diagnostics ... to fund a corporate lab for its genetic-based ... development is a critical component in the move ... the implementation of personalized medicine – a more ... , Indiegogo contributions will support Cellgen’s intent to ...
(Date:8/19/2014)... Research and Markets ... "Spectroscopy Equipment and Accessories - Global Strategic ... This report analyzes the ... in US$ Thousands by the following Product ... NMR-EPR Spectrometers, Near Infrared (NIR) Spectrometers, IR ...
Breaking Biology Technology:Intel and University of San Diego Bioengineering Department Release Case Study on Health Sciences Research 2Vascularization in Tissue Engineering Highlighted at 12th New Jersey Symposium on Biomaterials Science 2Cellgen Diagnostics Launches Indiegogo Crowdfunding Campaign for DNA Medical Testing Device 2Cellgen Diagnostics Launches Indiegogo Crowdfunding Campaign for DNA Medical Testing Device 3Global Spectroscopy Equipment and Accessories - Strategic Business Report 2014 2
... Jan. 2 CryoLife, Inc. (NYSE: CRY ... announced today,that it is scheduled to participate in ... Sir Francis Drake Hotel in Union Square, San,Francisco., ... operating officer and,chief financial officer of CryoLife, Inc., ...
... SAN FRANCISCO, Calif., Jan. 2 Exelixis,Inc. (Nasdaq: ... president and chief executive officer, will present at the ... 10:30 p.m. ET on,Thursday, January 10, 2008., The ... the Event,Calendar page under Investors on the Exelixis website ...
... Jan. 2 The following statement was issued,today by the ... Notice is hereby given that a class action lawsuit was ... of New York on,behalf of all purchasers of the securities ... February 17, 2006 through June 13, 2007,inclusive (the "Class Period")., ...
Cached Biology Technology:Shareholder Class Action Filed Against Sanofi-Aventis by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP 2Shareholder Class Action Filed Against Sanofi-Aventis by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP 3
(Date:8/21/2014)... University (ANU) team has successfully replicated one of the ... systems powered by sunlight which could manufacture hydrogen as ... sunlight. It is an exciting prospect to use them ... said Dr Kastoori Hingorani, from the ARC Centre of ... of Biology. , Hydrogen offers potential as a zero-carbon ...
(Date:8/21/2014)... resulting in severe abdominal pain, vomiting and systemic inflammation. ... diagnosed with the disease resulting in 1000 deaths. There ... intravenous fluid and nutritional support. , Dr Jason ... the research, said "The major causes of pancreatitis include ... intake combined with a high fat diet. In fact, ...
(Date:8/20/2014)... study of 158 pregnant teenagers in Rochester, NY, nearly ... consumption of ice, cornstarch, vacuum dust, baby powder and ... study. , Moreover, such teens had significantly lower iron ... nonfood substances. , Pregnant teens, regardless of pica, are ... to iron deficiency and anemia. Low iron in pregnant ...
Breaking Biology News(10 mins):Water and sunlight the formula for sustainable fuel 2Insulin offers new hope for the treatment of acute pancreatitis 2Pica in pregnant teens linked to low iron 2
... facing the world,s marine environments. Yet in the absence of ... plastic litter enter the ocean each year. ... Emmett Center on Climate Change and the Environment and UCLA,s ... impacts of plastic marine litter and offers domestic and international ...
... PARK, Calif. , Oct. 29, 2013 /PRNewswire-iReach/ -- ... buyout capital to emerging healthcare companies, announced today that ... Pharmaceuticals, has joined the Frazier Healthcare team as a ... long and distinguished track record as an entrepreneur, executive, ...
... and clinicians were unsung heroes during the early years (19771983) ... (VTEC). In an article published today in the Canadian ... microbiologist, documents the history of this area of study, ... Canadians to the science of what many people refer to ...
Cached Biology News:UCLA report urges new global policy effort to tackle crisis of plastic litter in oceans 2UCLA report urges new global policy effort to tackle crisis of plastic litter in oceans 3Frazier Healthcare Adds Carol Gallagher to its Life Science Team 2Frazier Healthcare Adds Carol Gallagher to its Life Science Team 3Canadian discoveries pivotal to the science of toxins and illness associated with E. coli 2
... 2'-O-Methyltransferase converts Cap 0 (or Cap 0-like) ... 1 structure has been shown to increase ... 50%. This improvement is seen in Cap ... Capping System as well as those Cap ...
Form: Ready to use Applications: ELISA...
RABBIT ANTI HALOPERIDOL...
Recombinant Mouse Serpin A1/alpha-1-Antitrypsin, CF Protein Family: Coagulation, Serine Protease Regulators...
Biology Products: